BCL2 and acute myeloid leukemia: Combining maplirpacept with the hypomethylating agent azacitidine or the Bcl-2 inhibitor venetoclax, both of which are used to treat newly diagnosed elderly unfit AML patients ineligible for intensive chemotherapy (17), enhanced the phagocytosis of the AML cell line MV-4-11 compared to either chemotherapy alone (Figures 5A, B).